KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables (2017 - 2026)

Moderna (MRNA) has disclosed Receivables for 10 consecutive years, with $242.0 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables fell 19.87% year-over-year to $242.0 million; the TTM value through Mar 2026 reached $242.0 million, down 19.87%, while the annual FY2025 figure was $226.0 million, 45.8% down from the prior year.
  • Receivables hit $242.0 million in Q1 2026 for Moderna, up from $226.0 million in the prior quarter.
  • Across five years, Receivables topped out at $3.2 billion in Q1 2022 and bottomed at $97.0 million in Q2 2025.
  • Average Receivables over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2023.
  • Year-over-year, Receivables tumbled 89.86% in 2023 and then soared 100.0% in 2024.
  • Moderna's Receivables stood at $1.4 billion in 2022, then grew by 13.62% to $1.6 billion in 2023, then plummeted by 74.62% to $417.0 million in 2024, then crashed by 45.8% to $226.0 million in 2025, then increased by 7.08% to $242.0 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $242.0 million, $226.0 million, and $2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.